Critical Imaging Risks In GLP-1 And Neurology Studies: What You Need To Know

In the evolving landscape of GLP-1 and neurology clinical trials, imaging has become a pivotal tool for evaluating both efficacy and safety. However, the complexities and potential pitfalls associated with imaging are frequently underestimated, often leading to unforeseen impacts on trial timelines, budgets, and outcomes. This presentation delves into the early indicators of imaging-related challenges and offers insights into preclinical strategies for effective risk mitigation.

Gain a comprehensive understanding of the expanding imaging requirements across various therapeutic areas as an expert panel guides clinical operations leaders through key learning objectives, including the identification of early imaging risks to prevent costly delays. The session highlights the importance of leveraging preclinical insights to inform trial design and strategically planning for the growing demands of imaging to enhance trial outcomes and regulatory compliance.